Carisma Therapeutics to remove Nasdaq listing for common stock

Carisma Therapeutics Inc. has submitted a Form 25 titled “Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934” for its common stock on The Nasdaq Stock Market LLC.

Rhea-AI Filing Summary

Carisma Therapeutics Inc. has submitted a Form 25 titled “Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934” for its common stock on The Nasdaq Stock Market LLC. The filing identifies the affected security as common stock with $0.001 par value per share and is signed by Interim Chief Executive Officer Steven Kelly, dated December 15, 2025.

Positive

• None.

Negative

• Carisma Therapeutics Inc. filed a Form 25 notification for removal from listing and/or registration of its common stock on The Nasdaq Stock Market LLC under Section 12(b) of the Exchange Act.

Insights

Equity listing analyst

Form 25 signals removal from Nasdaq listing and/or registration of Carisma Therapeutics common stock.

Carisma Therapeutics Inc. has filed a Form 25 titled “Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934.” The notice identifies The Nasdaq Stock Market LLC as the exchange and specifies that it applies to the issuer’s common stock with $0.001 par value per share.

The document is dated December 15, 2025 and signed by Interim Chief Executive Officer Steven Kelly, formally documenting this action. The filing focuses on the listing and/or registration status of the company’s common stock on Nasdaq, without providing additional context or financial information in this excerpt.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What action is Carisma Therapeutics Inc. (CARM) taking in this SEC filing?

Carisma Therapeutics Inc. has filed a Form 25 titled “Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934” for its common stock on The Nasdaq Stock Market LLC.

Which security is affected by Carisma Therapeutics Inc.'s Form 25 filing?

The filing applies to Carisma Therapeutics Inc.’s common stock with $0.001 par value per share.

On which exchange is the affected Carisma Therapeutics Inc. security listed in this notice?

The Form 25 identifies The Nasdaq Stock Market LLC as the exchange where the affected common stock is listed and/or registered.

Who signed Carisma Therapeutics Inc.'s Form 25 and in what capacity?

The Form 25 was signed by /s/ Steven Kelly, who is identified as the company’s Interim Chief Executive Officer.

When was Carisma Therapeutics Inc.'s Form 25 notification dated?

The notification is dated December 15, 2025.

Does Carisma Therapeutics Inc.'s Form 25 include financial results or earnings data?

No financial results or earnings data appear in this excerpt; it focuses on removal from listing and/or registration for the company’s common stock.

What is the stated purpose of the Form 25 used by Carisma Therapeutics Inc.?

The form is titled “Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934”, indicating it is used to address the listing and/or registration status of the company’s common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/15/2025 - 04:02 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR

REGISTRATION UNDER SECTION 12(b) OF THE

SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-36296

Carisma Therapeutics Inc.

The Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange

where security is listed and/or registered)

Carisma Therapeutics Inc.

3675 Market Street, Suite 401

Philadelphia, PA 19104

(267) 491-6422

(Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)

Common Stock, $0.001 par value per share

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

¨ 17 CFR 240.12d2-2(a)(1) 

¨ 17 CFR 240.12d2-2(a)(2) 

¨ 17 CFR 240.12d2-2(a)(3) 

¨ 17 CFR 240.12d2-2(a)(4) 

¨ Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.¹

x Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements of the Securities Exchange Act of 1934, Carisma Therapeutics Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

December 15, 2025				By		/s/ Steven Kelly				Interim Chief Executive Officer
Date						Name				Title

¹  Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.